日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Dual targeting of BRAF(V600E) and ferroptosis results in synergistic anticancer activity via iron overload and enhanced oxidative stress.

BRAF(V600E) 和铁死亡的双重靶向作用通过铁过载和增强氧化应激产生协同抗癌活性。

期刊:Journal of Experimental & Clinical Cancer Research
影响因子:12.8
doi:10.1186/s13046-025-03624-z
Hu Jiangnan, Ghosh Chandrayee, Khaket Tejinder P, Yang Zhongyue, Tabdili Yasmine, Alamaw Eden D, Boufraqech Myriem, Dixon Scott J, Kebebew Electron
肿瘤
BRAF
氧化应激
铁死亡
发表日期：2026
文献求助 收藏

Corrigendum to "Combination nitazoxanide and auranofin treatment has synergistic anticancer activity in anaplastic thyroid cancer through enhanced activation of oxidative stress that leads to apoptosis" [Cancer Letters 633 (2025) 217990]

对“尼他唑尼和金诺芬联合治疗通过增强氧化应激的激活导致细胞凋亡，对间变性甲状腺癌具有协同抗癌活性”的更正[Cancer Letters 633 (2025) 217990]

期刊:Cancer Letters
影响因子:10.1
doi:10.1016/j.canlet.2025.218159
Ghosh, Chandrayee; Khaket, Tejinder Pal; Gunda, Viswanath; Yang, Zhongyue; Hu, Jiangnan; Alamaw, Eden Demissie; Zhang, Lisa; Zhang, Ya-Qin; Shen, Min; Tabdili, Yasmine; Boufraqech, Myriem; Kassu, Rodas; Kebebew, Electron
肿瘤
凋亡
表观遗传
肿瘤免疫
氧化应激
甲状腺癌
细胞生物学
毒理研究
免疫/内分泌
发表日期：2026
文献求助 收藏

Combination nitazoxanide and auranofin treatment has synergistic anticancer activity in anaplastic thyroid cancer through enhanced activation of oxidative stress that leads to apoptosis.

硝唑尼特和金诺芬联合治疗对间变性甲状腺癌具有协同抗癌活性，其机制是通过增强氧化应激的激活，从而导致细胞凋亡。

期刊:Cancer Letters
影响因子:10.1
doi:10.1016/j.canlet.2025.217990
Ghosh Chandrayee, Khaket Tejinder Pal, Gunda Viswanath, Yang Zhongyue, Hu Jiangnan, Alamaw Eden Demissie, Zhang Lisa, Zhang Ya-Qin, Shen Min, Tabdili Yasmine, Boufraqech Myriem, Kassu Rodas, Kebebew Electron
甲状腺癌
细胞生物学
Apoptosis
凋亡
氧化应激
发表日期：2025
文献求助 收藏

CRISPR-Based Gene Dependency Screens reveal Mechanism of BRAF Inhibitor Resistance in Anaplastic Thyroid Cancer.

基于 CRISPR 的基因依赖性筛选揭示了间变性甲状腺癌中 BRAF 抑制剂耐药的机制

期刊:
影响因子:
doi:10.1101/2025.06.26.661609
Noronha Shawn, Liu Yue, Geneti Gaga, Li Haojian, Wu Xiaolin, Sun David, Gujar Vaibhavi, Furusawa Takashi, Lobanov Alexei, Cam Maggie, Pal Lipika R, Nair Nishanth, Day Chi-Ping, Ruppin Eytan, Gosh Chandrayee, Hu Jiangnan, Kumar Suresh, Andresson Thorkell, Chan King, O'Neill Maura, Chari Raj, Pommier Yves, Del Rivero Jaydira, Weyemi Urbain, Kebebew Electron, Boufraqech Myriem
肿瘤
甲状腺癌
肿瘤免疫
发表日期：2025
文献求助 收藏

Metabolism-focused CRISPR screen unveils mitochondrial pyruvate carrier 1 as a critical driver for PARP inhibitor resistance in lung cancer.

以代谢为重点的 CRISPR 筛选揭示线粒体丙酮酸载体 1 是肺癌中 PARP 抑制剂耐药性的关键驱动因素

期刊:Molecular Carcinogenesis
影响因子:3.2
doi:10.1002/mc.23705
Furusawa Takashi, Cavero Renzo, Liu Yue, Li Haojian, Xu Xia, Andresson Thorkell, Reinhold William, White Olivia, Boufraqech Myriem, Meyer Thomas J, Hartmann Oliver, Diefenbacher Markus E, Pommier Yves, Weyemi Urbain
代谢
肺癌
线粒体
发表日期：2024
文献求助 收藏

CRISPR metabolic screen identifies ATM and KEAP1 as targetable genetic vulnerabilities in solid tumors

CRISPR 代谢筛选确定 ATM 和 KEAP1 是实体肿瘤中可靶向的遗传弱点

期刊:Proceedings of the National Academy of Sciences of the United States of America
影响因子:
doi:10.1073/pnas.2212072120
Haojian Li, Yue Liu, Yunjie Xiao, Crystal N Wilson, Hui Jen Bai, Maxwell D Jones, Shihchun Wang, Jennie E DeVore, Esther Y Maier, Stephen T Durant, Myriem Boufraqech, Urbain Weyemi
代谢
肿瘤
发表日期：2023
文献求助 收藏

Preclinical assessment of synergistic efficacy of MELK and CDK inhibitors in adrenocortical cancer

MELK 和 CDK 抑制剂对肾上腺皮质癌的协同作用的临床前评估

期刊:Journal of Experimental & Clinical Cancer Research
影响因子:11.4
doi:10.1186/s13046-022-02464-5
Dipranjan Laha, Robert R C Grant, Prachi Mishra, Myriem Boufraqech, Min Shen, Ya-Qin Zhang, Matthew D Hall, Martha Quezado, Michelly Sampaio De Melo, Jaydira Del Rivero, Martha Zeiger, Naris Nilubol
肿瘤
肾癌
发表日期：2022
文献求助 收藏

Histone H2AX promotes metastatic progression by preserving glycolysis via hexokinase-2

组蛋白 H2AX 通过己糖激酶-2 保留糖酵解，促进转移进展

期刊:Scientific Reports
影响因子:3.8
doi:10.1038/s41598-022-07675-6
Yue Liu, Haojian Li, Crystal N Wilson, Hui Jen Bai, Myriem Boufraqech, Urbain Weyemi
表观遗传
发表日期：2022
文献求助 收藏

A Combinatorial Strategy for Targeting BRAF (V600E)-Mutant Cancers with BRAF(V600E) Inhibitor (PLX4720) and Tyrosine Kinase Inhibitor (Ponatinib)

采用 BRAF (V600E) 抑制剂 (PLX4720) 和酪氨酸激酶抑制剂 (Ponatinib) 联合治疗 BRAF (V600E) 突变型癌症的联合策略

期刊:Clinical Cancer Research
影响因子:10.2
doi:10.1158/1078-0432.CCR-19-1606
Ghosh, Chandrayee; Kumar, Suresh; Kushchayeva, Yevgeniya; Gaskins, Kelli; Boufraqech, Myriem; Wei, Darmood; Gara, Sudheer Kumar; Zhang, Lisa; Zhang, Ya-Qin; Shen, Min; Mukherjee, Sanjit; Kebebew, Electron
信号转导
肿瘤
BRAF
肿瘤免疫
发表日期：2020
文献求助 收藏

New Therapies for Advanced Thyroid Cancer

晚期甲状腺癌的新疗法

期刊:Frontiers in Endocrinology
影响因子:4.6
doi:10.3389/fendo.2020.00082
Laha, Diprajan; Nilubol, Naris; Boufraqech, Myriem
甲状腺癌
肿瘤
肿瘤免疫
免疫/内分泌
发表日期：2020
文献求助 收藏